

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

SACKEY, Ebenezer O

George E. LEE, et. al.

Art Unit:

1626

Application No.:

oplication of

10/088,369

Filed:

December 23, 2002

Title:

THIENOISOXAZOLEPHENOXY UNSUBSTITUTED ETHYL AND PROPYL

DERIVATIVES USEFUL AS D4 ANTAGONISTS

with the United States Postal Service with sufficient postage

for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the

Certificate of Mailing or Transmission I hereby certify that this correspondence is being deposited

USPTO, on the date indicated below. Date of Deposit August 25, 2005

Printed Name of Person Signing Certificate Brian Pritchett

Signature

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2965 (908) 231-2626 Telefax

Aventis Docket No. HMR2021 US PCT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

an of

George E. LEE, et. al.

Examiner: Art Unit:

SACKEY, Ebenezer O

Application No.:

10/088,369

Filed:

December 23, 2002

Title:

THIENOISOXAZOLEPHENOXY

UNSUBSTITUTED ETHYL AND PROPYL **DERIVATIVES USEFUL AS D4 ANTAGONISTS** I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

1626

August 25, 2005

Brian Pritchett Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

10088369 08/30/2005 NNGUYEN1 00000056 181982

01 FC:1806

180.00 DA

 \boxtimes This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or (3)This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. HMR2021 US PCT

authorized.

Please type a	plus sign (+) inside this box ->	V

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

AUG 2 9 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 Sheet of


Complete if Known			
Application Number	10/088,369		
Filing Date	12-23-2002		
First Named Inventor	LEE, et. al.		
Group Art Unit	1626		
Examiner Name	SACKEY, Ebenezer O.		
Attorney Docket Number	USHMR2021 - US - PCT		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,256,672		WETTLAUFER, et, al.	10-26-1993	
		5,576,319		BAKER, et. al.	11-19-1996	_
		5,780,474		PEGLION, et. al.	07-14-1998	
		5,114,936		WETTLAUFER, et, al.	05-19-1992	
		5,143,923		HRIB, et. al.	09-01-1992	
		5,177,088		EFFLAND, et. al.	01-05-1993	
		5,180,834		WETTLAUFER, et, al.	01-19-1993	₩
		5,225,412		HRIB, et. al.	07-06-1993	
		5,328,920		EFFLAND, et. al.	07-12-1994	
		6,022,880		EFFLAND, et. al.	02-08-2000	
				,		
				•		
		ļ		•	_	
		-				
		· · · · · · · · · · · · · · · · · · ·				

	Foreign Patent Document							
Examiner Initials*		Office		Kind Code ⁵		Cited Document	Where Relevant Passages or Relevant	T6
		JP	10095770		MASANORI, et. al.	04-14-1998		
		wo	92/08718		HOWARD, et. al.	05-29-1992	-	
		wo	97/23482		SANNER, et. al.	07-03-1997		\top
		wo	97/40027		LEYSEN, et. al.	10-30-1997		
		wo	99/40067		DEN HARTOG, et. al.	08-12-1999		
		<u> </u>						
		 				ļ		₩
i i		1						i i

Examiner	Date	
Signature	 Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ->	2 (3 AUG 2 9 2
Under the Paperwork Reduction Act of 1995, no pe	ersons required to res
Substitute for form 14409/PTO	TRADEM

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Substitute for form 1449B/PTO

2

Sheet

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

collection of information unless it contains a valid OMB control number.

· · · · · · · · · · · · · · · · · · ·	omplete if Known
Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Ebenezer O.
Attorney Docket Number	USHMR2021 - US - PCT

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		KONGSAMUT, S., et. al., Iloperidone Binding to Human and Rat Dopamine and 5-HT Receptors, Database Chemabs online! Chemical Abstracts Service, Columbus, Ohio, US retrieved from STN Database Accession No. 126:70003 XP002154323 * Eur. J. Pharmacol. (1996) Vol.317, (2/3)	:
-			
			<u> </u>
Examine		Date	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.